A Randomized Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence, and Tolerability of IHL-42X Compared with the Reference Drugs in Healthy Volunteers.

Mbogo GW, Sallama A, Asvadi P, May N, Redzepagic E, Ryan P, Bleackley MR

Open source

DOI
10.1007/s40261-026-01595-3
Published
2026 Sep 12
Container
Clinical drug investigation
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40261-026-01595-3,
  title = {A Randomized Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence, and Tolerability of IHL-42X Compared with the Reference Drugs in Healthy Volunteers.},
  author = {Mbogo GW and Sallama A and Asvadi P and May N and Redzepagic E and Ryan P and Bleackley MR},
  year = {2026},
  journal = {Clinical drug investigation},
  doi = {10.1007/s40261-026-01595-3},
  url = {https://doi.org/10.1007/s40261-026-01595-3}
}

RIS

TY  - JOUR
TI  - A Randomized Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence, and Tolerability of IHL-42X Compared with the Reference Drugs in Healthy Volunteers.
AU  - Mbogo GW
AU  - Sallama A
AU  - Asvadi P
AU  - May N
AU  - Redzepagic E
AU  - Ryan P
AU  - Bleackley MR
PY  - 2026
JO  - Clinical drug investigation
DO  - 10.1007/s40261-026-01595-3
UR  - https://doi.org/10.1007/s40261-026-01595-3
ER  - 

APA

GW, M., A, S., P, A., N, M., E, R., P, R., & MR, B. (2026). A Randomized Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence, and Tolerability of IHL-42X Compared with the Reference Drugs in Healthy Volunteers.. Clinical drug investigation. https://doi.org/10.1007/s40261-026-01595-3

Source records